UBC

AI-powered evidence. **Decision-ready results.**

UBC delivers AI-powered systematic literature reviews and full-spectrum evidence development —with the scientific rigor regulators demand.

The Evidence Challenge

THE SLR BOTTLENECK

Manual screening of thousands of abstracts creates delays that push back HTA submissions, regulatory filings, and market access timelines by months.

RISING REGULATORY STANDARDS

FDA, EMA, Health Canada, CDA-AMC, and NICE all require HTA-grade evidence synthesis with reproducible, PRISMA-compliant methodologies.

The UBC Advantage

A Unified Approach With Evidinno

We replace fragmentation with **a single, AI-powered platform** that combines technology with PhD-level scientific expertise to deliver regulatory-grade evidence at unprecedented speed.

What You Get

AI — AI-Powered Evidence Synthesis
Systematic literature reviews in weeks, not months. AI-assisted screening with PRISMA-compliant methodology.

PhD — Speed & Scientific Rigor
Every deliverable reviewed by PhD epidemiologists, biostatisticians, and health economists Zero junior-level work.

360 — A Strategic Advantage
Full-spectrum evidence partner from SLR through HEOR, market access, RWE, and post-market surveillance.

Full-Spectrum Capabilities



AI Technology + PhD Expertise + Integrated Strategy = **The Most Comprehensive Evidence Development Available**

What Makes
Our Approach Different?

Our AI-powered technology and PhD-level expertise are designed to eliminate the evidence bottleneck.

Evidence Across the Product Lifecycle

End-to-end support from clinical development through post-market evidence generation



The Core of Our Solution

Full-Spectrum Integration

The optimal combination.

Combine Evidinno's HEOR and evidence synthesis expertise with UBC's RWE, REMS, patient access, and post-market infrastructure — one integrated partner.

Regulatory-Grade Quality

The Power of Rigor.

Deliverables built for FDA, EMA, Health Canada, CDA-AMC, and NICE submissions. Every output validated by PhD scientists with zero junior-level work.

AI-Powered SLR

Weeks, not months.

AI-assisted screening and extraction dramatically accelerates systematic literature reviews while maintaining PRISMA compliance and full reproducibility.

Complex Analytics

Precision for every dataset.

NMA, ITC, predictive modeling, surrogate endpoint analyses, and health economic modeling (BIM, CEA, CUA) — advanced methods for your toughest evidence needs.

Your Benefits

For Biopharma Leaders

End-to-end evidence partner from SLR through HTA submission, regulatory filing, and post-market — reducing vendor fragmentation and accelerating timelines.

For HEOR and Evidence Teams

AI-accelerated SLRs, NMAs, and complex analyses with PhD oversight on every deliverable. PRISMA, CHEERS, and global HTA agency standards.

Ready to Get Started?

Your pipeline can't wait. Your evidence can't be compromised.

Discover how Evidinno + UBC can transform your evidence strategy.

ubc.com/contact-us

ubc.com

EVIDINNO a UBC company

UBC